Skip to main content

Table 2 p63 immunostaining and tumor phenotype

From: p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors

   n p63 IHC result (%) p
negative weak moderate strong
Urinary bladder cancer all cancers 1038 13.4 5.9 9.1 71.7  
pTa G2 low 116 0.0 0.0 2.6 97.4 <0.0001
pTa G2 high 106 0.0 0.9 8.5 90.6  
pTaG3 132 9.8 6.1 15.2 68.9  
pT≥2 G3 672 18.6 7.0 9.2 65.2  
pT≥2 G3 sarcomatoid 18 44.4 11.1 5.6 38.9 0.0052 (vs >pT2G3)
pT≥2 G3 small cell ca. 18 88.9 5.6 5.6 0.0 <0.0001 (vs ≥pT2G3)
pN0 111 13.5 8.1 9.0 69.4 0.9138
pN+ 71 15.5 5.6 8.5 70.4  
Pancreatic adenocarcinoma all cancers 422 84.4 5.7 3.1 6.9  
pT1 12 91.7 0 0 8.3 0.2753
pT2 63 92.1 3.2 1.6 3.2  
pT3 318 82.4 6.9 3.1 7.5  
pT4 27 85.2 0 7.4 7.4  
G1 12 100 0 0 0 0.3483
G2 295 82.7 7.1 3.1 7.1  
G3 92 85.9 3.3 2.2 8.7  
pN0 91 85.7 3.3 4.4 6.6 0.5777
pN+ 329 83.9 6.4 2.7 7  
pM0 334 83.2 6.3 3 7.5 0.515
pM1 87 88.5 3.4 3.4 4.6  
R0 212 83.5 7.1 2.4 7.1 0.5384
R1 174 85.6 4.6 4 5.7  
Endometrial cancer, endometrioid all cancers 160 83.1 4.4 12.5 0.0  
pT1 101 83.2 3.0 13.9 0.0 0.6733
pT2 23 87.0 4.3 8.7 0.0  
pT3-4 33 78.8 9.1 12.1 0.0  
pN0 43 83.7 4.7 11.6 0.0 0.3704
pN+ 28 75.0 14.3 10.7 0.0  
Ovarian cancers, serous all cancers 374 91.7 5.1 2.4 0.8  
pT1 29 93.1 3.4 3.4 0.0 0.2274
pT2 39 84.6 5.1 10.3 0.0  
pT3 257 91.8 5.4 1.6 1.2  
pN0 81 88.9 4.9 4.9 1.2 0.3673
pN+ 166 91.0 6.6 1.2 1.2  
Stomach cancer all cancers 355 96.1 1.1 0.6 2.3  
diffuse 85 97.6 2.4 0.0 0.0 0.1478
intestinal 79 97.5 0.0 0.0 2.5  
mixed 56 94.6 1.8 0.0 3.6  
pT1-2 57 96.5 0.0 1.8 1.8 0.3119
pT3 117 94.9 0.9 0.9 3.4  
pT4 118 96.6 2.5 0.0 0.8  
pN0 74 100.0 0.0 0.0 0.0 0.0208
pN1 62 93.5 1.6 3.2 1.6  
pN2 55 92.7 0.0 0.0 7.3  
pN3 101 96.0 3.0 0.0 1.0